Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ViewRay, Inc.
  6. Summary
    VRAY   US92672L1070

VIEWRAY, INC.

(VRAY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
5.58(c) 5.78(c) 5.58(c) 5.25(c) 5.14(c) Last
2 589 921 1 879 538 1 105 053 1 800 609 2 435 385 Volume
-0.18% +3.58% -3.46% -5.91% -2.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 69,5 M - -
Net income 2021 -107 M - -
Net cash position 2021 98,9 M - -
P/E ratio 2021 -7,79x
Yield 2021 -
Sales 2022 97,9 M - -
Net income 2022 -108 M - -
Net cash position 2022 66,1 M - -
P/E ratio 2022 -7,93x
Yield 2022 -
Capitalization 909 M 909 M -
EV / Sales 2021 11,7x
EV / Sales 2022 8,61x
Nbr of Employees 236
Free-Float 97,4%
More Financials
Company
ViewRay, Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. MRIdian system is comprised of... 
More about the company
Ratings of ViewRay, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about VIEWRAY, INC.
11/24ViewRay Announces MRIdian MR-Guided Radiation Therapy Surpasses 2,300 Pancreatic Cancer..
PR
11/23ViewRay Gets $10.5 Million From Underwriters' Option Exercise After Stock Offering
MT
11/23ViewRay Announces Closing of Full Exercise of Underwriters' Option to Purchase Addition..
PR
11/19INSIDER BUY : Viewray
MT
11/19ViewRay Announces Closing of Public Offering of Common Stock
PR
11/19VIEWRAY, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17ViewRay Prices Public Offering at $5.60/Share, Expects $70 Million Gross Proceeds
MT
11/16ViewRay Announces Pricing of Public Offering of Common Stock
PR
11/16ViewRay Plans Common Stock Offering
MT
11/16ViewRay Announces Proposed Public Offering of Common Stock
PR
11/05VIEWRAY, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/05ViewRay, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/04VIEWRAY : Q3 Earnings Snapshot
AQ
11/04ViewRay Reports Third Quarter 2021 Results - Form 8-K
PU
11/04ViewRay's Q3 Net Loss Shrinks as Revenue Jumps; 2021 Revenue Guidance Affirmed
MT
More news
News in other languages on VIEWRAY, INC.
11/23ViewRay lève 10,5 millions de dollars suite à l'exercice par les preneurs fermes de l'o..
11/19ACHATS D'INITIÉS : Viewray
11/16ViewRay propose un placement d'actions ordinaires
11/04ViewRay réduit sa perte nette au troisième trimestre et augmente son chiffre d'affaires..
11/04Earnings Flash (VRAY) VIEWRAY annonce un chiffre d'affaires de 19,2 millions de dollars..
More news
Analyst Recommendations on VIEWRAY, INC.
More recommendations
Chart VIEWRAY, INC.
Duration : Period :
ViewRay, Inc. Technical Analysis Chart | VRAY | US92672L1070 | MarketScreener
Technical analysis trends VIEWRAY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,14 $
Average target price 8,57 $
Spread / Average Target 66,8%
EPS Revisions
Managers and Directors
Scott William Drake President, Chief Executive Officer & Director
Zachary Stassen Chief Financial Officer
Daniel Jeffrey Moore Chairman
James F. Dempsey Chief Scientific Officer
Martin Fuss Chief Medical Officer
Sector and Competitors